(Adds details on Trillium’s drug candidates, share movement)
Aug 23 (Reuters) – Pfizer Inc said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies.
Pfizer, which acquired a $25 million stake in Trillium last year, will buy the remaining outstanding shares for $18.50 apiece, representing a 203.8% premium on the stock’s last closing price.
Pfizer expects to benefit from Canada-based Trillium’s…
Source link
